SecBot SecBot

IBIO

iBio, Inc.
Nasdaq· Pharmaceutical Preparations· Inc. DE· CIK 0001420720 Biotech & Drug Discovery
$0.7070 −0.01 (−1.81%)
Oct 26 4:00 PM ET · prev $0.7200
Market cap
$50.4M
Micro cap
Consensus
Buy
93% Buy or better · 15 analysts
Median target
$6.00
+749% · range $4.20–7.00
Next earnings
Nov 10
in 15 days · EPS est. −$0.08
1 year
−44.8%
from $1.28 · Oct 27
30 days
−39.6%
from $1.17
52-week range
$0.7070–3.07
at the low
Avg volume 20D
874.5K
Oct 7 spike 2.71M
Short interest
🔒 Subscribers only
Insider net
+$98.1K
3 buyers · 0 sellers · 12 mo
New fund stakes
0
Q2 2026 13F · 0 exits
Filing reports
15
analyzed by SecBot
SecBot read BULLISH 6 reports · 90 days
Balance 0 bearish · 1 bullish · 5 neutral oldest → newest, height = score
Avg score ·High conf. 3/6 ·Next Earnings date, Nov 10, 2026
Strongest BULLISH iBio released preclinical body-composition data from an obese NHP study of IBIO-610, a first-in-class…
All reports →

Price

Daily candles with volume. Pins mark insider trades, rating changes, 13F stakes, reports, catalysts and short-interest jumps.

Signal stack

Where each data set points today.

  • InsidersBULLISH

    3 insiders bought $98.1K at an average $1.92. No open-market sales. Price is 63% below their cost.

  • InstitutionsBULLISH

    Q2 2026: 11 added (0 new), 4 trimmed or exited.

  • AnalystsBULLISH

    14 of 15 rate it Buy or better. Every target is above the price.

  • EstimatesRISING

    Current-quarter EPS estimate −$0.077 → −$0.076 over 90 days.

  • TrendDOWNTREND

    39% below its 50-day average. New closing low $0.7070 on Oct 26.

Who's buying

13F· Q2 2026
0
new positions
0
exits
FundMoveSharesValue
VANGUARD CAPITAL MANAGEMENT LLCADD2,098,151$3.7M
CITADEL ADVISORS LLCADD1,384,029$2.4M
BANK OF AMERICA CORP /DE/DOUBLED1,121,492$2.0M
MARSHALL WACE, LLPADD904,132$1.6M
GEODE CAPITAL MANAGEMENT, LLCADD500,816$876.6K
Walleye Capital LLCADD500,375$875.7K
VANGUARD FIDUCIARY TRUST COADD286,875$502.0K
BlackRock, Inc.ADD242,016$423.5K

Quarterly 13F filings are due 45 days after each quarter ends.

The Street

15 analysts
Buy 93% rate it Buy or better
Strong Buy4Buy10Hold1Sell0Strong Sell0
12-month targets · 9 analysts

Price is below the lowest target. Median implies +749%.Targets as of Oct 26, 2026.

Recent actions
DateFirmActionRating
Sep 17, 2026HC Wainwright & Co.
INITIATE
INITIATEBuy
Jul 2, 2026Chardan Capital
MAINTAIN
MAINTAINBuy
Jun 8, 2026Raymond James
INITIATE
INITIATEOutperform

Insider ledger

Form 4
$98.1K
bought · 3 insiders
$0
sold · 0 insiders
−63.2%
vs their $1.92 cost
DateInsiderTypeValue
Oct 14, 2026
Sender Gary
Director
AWARD38,000 sh
Oct 14, 2026
Parada Antonio Bernardino Guimaraes
Director
AWARD38,000 sh
Oct 14, 2026
Clark William D
Director
AWARD38,000 sh
Oct 14, 2026
Arkowitz David
Director
AWARD38,000 sh
Oct 14, 2026
Kropotova Alexandra
Director
AWARD38,000 sh
Oct 14, 2026
Stoner Elizabeth
Director
AWARD38,000 sh
Jul 31, 2026
Carr Molly
Chief Medical Officer
AWARD430,000 sh
May 18, 2026
Stoner Elizabeth
Director
AWARD60,000 sh

Earnings setup

Estimates
Nov 10
reports in 15 days
−$0.08
EPS estimate, this quarter
+2%
estimate change, 90 days
Current-quarter EPS estimate
PeriodEPS est.Range30D rev.Revenue
Current Q-$0.08-$0.10–-$0.05+5.4%$16.7K
Next Q-$0.08-$0.12–-$0.06+3.7%$0.00
Current FY-$0.38-$0.85–-$0.22+5.1%$25.0K
Next FY-$0.61-$1.00–-$0.26-34.2%$20.0K

Short side

FINRA· Oct 15, 2026
🔒 Subscribers only
shares short
Recent activity
The latest filings, insider trades, analyst actions, press and options flow — newest first.
Oct 19, 2026 SEC
iBio, Inc. held its 2026 Annual Meeting on October 14, 2026, where stockholders approved an increase in authorized…
8-K — Impact 3/10
Oct 14, 2026 SEC
Coastlands Capital LP disclosed a new 9.72% passive stake in iBio, Inc. via a Schedule 13G filed October 14, 2026…
SC 13G — Impact 4/10
Oct 14, 2026 Insider
Sender Gary was granted 38,000 shares
Director
Oct 14, 2026 Insider
Parada Antonio Bernardino Guimaraes was granted 38,000 shares
Director
Oct 14, 2026 Insider
Clark William D was granted 38,000 shares
Director
Oct 13, 2026 SEC
iBio released preclinical body-composition data from an obese NHP study of IBIO-610, a first-in-class Activin E…
8-K — Impact 5/10
Sep 3, 2026 Earnings calendar
IBIO Q4 2026 Earnings Scheduled — 2026-09-03
Jun 30, 2026 Inst.
VANGUARD CAPITAL MANAGEMENT LLC — ADD
2,098,151 shares ($3.7M)
Catalysts
Scheduled dates and disclosed events: earnings, FDA and trial readouts, halts, press releases. Colored dot = impact.
Upcoming
Nov 10, 2026
Earnings date
IBIO Q1 2027 Earnings Scheduled — 2026-11-10
Recent
Sep 3, 2026
Earnings date
IBIO Q4 2026 Earnings Scheduled — 2026-09-03
Aug 28, 2026
Earnings
iBio Reports Fiscal Year 2026 Financial Results and Provides Corporate Update
SAN DIEGO, Aug. 28, 2026 (GLOBE NEWSWIRE) -- iBio, Inc. (NASDAQ: IBIO), a clinical-stage biotechnology company developing long-acting antibody…
Jul 1, 2026
Press release
iBio Reports Single Dose of IBIO-610 Achieved Near-Complete Active Activin E Inhibition Through Eight Weeks in Obese NHP Study
Single-dose IBIO-610 achieved up to 98% inhibition of active Activin E through eight weeks, supporting a differentiated, long-acting antibody approach
Jun 30, 2026
Short interest
Short Interest: IBIO up 25% to 4.7M shares
Settlement 2026-06-30 | Days to cover: 5.07 | ≈9.45% of shares outstanding (est.)
Jun 2, 2026
Press release
iBio to Participate in Upcoming Healthcare Investor Conferences
SAN DIEGO, June 02, 2026 (GLOBE NEWSWIRE) -- iBio, Inc. ( NASDAQ: IBIO ) (“iBio” or the “Company”), an AI-driven innovator developing therapies for…

SecBot reports

15 filings · 1 press release · 3 bullish · 2 bearish · 1 mixed · 9 neutral
All IBIO filing & press-release reports (16)